Immune Treatment of Brain Metastasis of Lung Cancer Combined With Large-segmentation Precision Radiotherapy

Multi-omics Evaluation System and Preferred Mode of Immune Treatment of Brain Metastasis of Lung Cancer Combined With Large-segmentation Precision Radiotherapy

This is a prospective multicenter clinical study. This study aims to construct an auxiliary decision-making system for lung cancer immunotherapy combined with radiotherapy by fusing three modes of imagomics, clinicopathological features, and molecular pathological features.

Inclusion Criteria:

• Age ≥ 18 years of age on day of signing informed consent
• Histopathology confirmed non-small cell lung cancer
• Asymptomatic brain metastases
• EGFR/ALK ROS1 driver gene mutation negative
• RECIST 1.1 based available assessment of lesions
• ECOG 0-1
• Brain metastases 1-4
• Single lesion ≤4cm

Exclusion Criteria:

• Patients with contraindication of chemotherapy Pregnant or breast feeding women